| Document |
Document Title |
|
WO/2021/250102A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds (formula (I)), and their use as MCL-1 inhibitors, useful for treating disease...
|
|
WO/2021/250399A1 |
The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds ...
|
|
WO/2021/249234A1 |
A compound represented by general formula (I) or stereisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An applica...
|
|
WO/2021/252661A1 |
The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, incl...
|
|
WO/2021/250635A1 |
The present disclosure is in the field of pharmaceutical and chemical sciences. The present disclosure generally relates to the synthesis of therapeutic agents, processes for preparing said agents, compositions comprising said therapeuti...
|
|
WO/2021/249492A1 |
Provided are a new methyl-substituted benzobisoxazole compound and the use thereof in the preparation of drugs for treating related diseases. Specifically disclosed is a compound represented by formula (P) or a pharmaceutically acceptabl...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/205631A9 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on STING. As a result of having performed thoroughgoing studies, the inventors discovered, ...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/244645A1 |
A novel five-membered heteroaromatic imidazole compound and use thereof in preparing a medicament for treating related diseases. Specifically, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/216665A9 |
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound heali...
|
|
WO/2021/238908A1 |
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...
|
|
WO/2021/242955A1 |
The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, me...
|
|
WO/2021/241741A1 |
The present invention provides a photoelectric conversion element having excellent sensitivity, an image sensor, an optical sensor, and a compound. The photoelectric conversion element of the present invention has a conductive film, a ph...
|
|
WO/2021/233227A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2021/230512A1 |
Provided is a benzazole derivative that effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials inside an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/228123A1 |
Provided are a compound for adjusting the activity of an NMDA receptor, and a pharmaceutical composition and the use thereof. In particular, provided are a compound as represented by formula I, or a pharmaceutically acceptable salt or es...
|
|
WO/2021/230511A1 |
Provided is a benzazole derivative which contributes to improving substantial optical efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention comprises...
|
|
WO/2021/230035A1 |
(I) (In formula (I), X1 and X2 are, independently from each other, a fluorine atom, a cyano, an alkoxy that may be substituted by D, an amino that may be substituted by D, an acylamino that may be substituted by D, an aryloxy that may be...
|
|
WO/2021/226168A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2021/224291A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2021/224501A1 |
The present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease involving gram-positive bacteria.
|
|
WO/2021/225833A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Z that can be used to prepare them. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates there...
|
|
WO/2021/226009A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Com...
|
|
WO/2021/225823A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound D, wherein OPG and R1 are described herein. Compound D can be usefu...
|
|
WO/2021/222353A1 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2021/222366A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2021/221032A1 |
The present invention addresses the problem of providing a photoelectric conversion element that exhibits excellent external quantum efficiency and responsiveness with respect to light having any wavelength among a red wavelength range, ...
|
|
WO/2021/222614A1 |
Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
|
|
WO/2021/222363A1 |
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods...
|
|
WO/2021/214284A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2021/213518A1 |
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...
|
|
WO/2021/207453A1 |
The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
|
|
WO/2021/204589A1 |
The present invention relates to substituted thiazolopyridines of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their use as herbici...
|
|
WO/2021/198213A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/201036A1 |
The present invention provides a target protein degradation inducing compound which is a bifunctional compound having, at one terminal, a portion that binds to VHL which is a substrate recognition protein of a ubiquitin ligase complex an...
|
|
WO/2021/202501A1 |
In accordance with the present disclosure, compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficac...
|
|
WO/2021/202480A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2021/194914A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical ...
|
|
WO/2021/190616A1 |
The present disclosure provides methods for inhibiting CK1 delta or CK1 epsilon activity, comprising administering an effective amount of the compound of Formula (I) to (IV), or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/190727A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
|
WO/2021/183555A1 |
This disclosure provides an ocular tissue depot of a selected complement factor D (CFD) inhibitor for the extended treatment of an ocular disorder mediated by complement factor D. In particular, the disclosure includes the creation of a ...
|
|
WO/2021/180147A1 |
The present invention provides an influenza virus inhibitor, and the therapeutic effect of the inhibitor in a patient infected with influenza viruses.
|
|
WO/2021/180143A1 |
The present invention provides a JAK kinase inhibitor and a preparation and application thereof, and the present invention specifically provides a compound having a structure represented in the following formula I, an enantiomer thereof,...
|
|
WO/2021/177390A1 |
A compound according to the present invention has a chemical structure which, when viewed macroscopically, is arranged such that a chelating portion is positioned in the center of the structure, an atomic group containing an albumin bind...
|
|
WO/2021/178684A1 |
The disclosure relates to selective small molecule dual activators of human constitutive androstane receptor (hCAR) and nuclear factor erythroid 2-related factor 2 (Nrf2), pharmaceutical compositions thereof, and use thereof for the trea...
|
|
WO/2021/170658A1 |
The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating ...
|
|
WO/2021/168074A1 |
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula ...
|
|
WO/2021/164746A1 |
The present application describes a substituted aryl compound used as an RAD51 inhibitor and a pharmaceutically acceptable salt thereof. The compound has the structure as represented by Formula (I) and has the substituents and structural...
|
|
WO/2021/160132A1 |
Disclosed in the present invention are a heterocyclic compound, a preparation method therefor and use thereof. The present invention provides a heterocyclic compound as shown in formula I or a pharmaceutically acceptable salt thereof. Th...
|
